Tubocurarine
Tubocurarine is a non-depolarizing neuromuscular blocking agent derived from curare that competitively antagonizes nicotinic acetylcholine receptors at the neuromuscular junction, causing skeletal muscle paralysis. It was the first purified neuromuscular blocker used clinically to provide muscle relaxation during surgical procedures and mechanical ventilation. It has largely been replaced by newer agents with fewer cardiovascular side effects.
Peso molecular
609,7000 g/mol
LogP
6,00
TPSA
80,60 Ų
Regla de cinco de Lipinski
No cumple
Mecanismo de acción
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Estructura 2D
Cite this structure
Embed this structure
SMILES
COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C
InChI
InChI=1S/C37H40N2O6/c1-38-14-12-24-19-32(42-4)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-37-35-25(20-34(43-5)36(37)41)13-15-39(2,3)29(35)17-23-8-11-30(40)31(18-23)45-33/h6-11,18-21,28-29H,12-17H2,1-5H3,(H-,40,41)/p+1/t28-,29+/m0/s1
Molecular Formula
C37H41N2O6+
HBD / HBA
2 / 7
Enlaces Rotables
2
Átomos Pesados
45
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
Tubocurarine is a non-depolarizing neuromuscular blocking agent derived from curare that competitively antagonizes nicotinic acetylcholine receptors at the neuromuscular junction, causing skeletal muscle paralysis. It was the first purified neuromuscular blocker used clinically to provide muscle relaxation during surgical procedures and mechanical ventilation. It has largely been replaced by newer agents with fewer cardiovascular side effects.
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Yes, Tubocurarine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL339427. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6000. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tubocurarine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tubocurarine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tubocurarine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tubocurarine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tubocurarine"></drugfyi-drug>